Objective. To investigate the pathogenic mechanism of reactive arthritis after instillation of Calmette-Guérin bacillus (BCG). Although the clinical features of reactive arthritis after BCG therapy are well described, only a few reports have studied the possible pathogenic mechanisms.
Immunotherapy with Calmette-Guérin bacillus (BCG) is the most effective means currently available for the treatment of superficial bladder cancer w1x. However, this therapy is associated with several side-effects, including joint symptoms w2x. The development of inflammatory arthritis is a rare but well-known complication in patients treated for superficial bladder cancer by intravesical BCG immunotherapy w2x. Although the clinical features of this type of arthritis have been described previously in the medical literature w3x, only a few reports have provided data on possible pathogenic mechanisms w4, 5x.
A patient who developed inflammatory polyarthritis following intravesical administration of BCG immunotherapy for bladder cancer is reported. A detailed flow cytometry analysis of peripheral blood (PBMC) and synovial fluid mononuclear cells (SFMC) was performed. Furthermore, we studied the response of short-term T-cell lines (TCL) from this patient to different mycobacterial antigens wBCG and tuberculin (purified protein derivative, PPD)x and to human heat shock protein 60 (hsp-60).
Materials and methods
Case report A 61-yr-old man was admitted to the hospital because of a 1-week history of fever and polyarthritis. He had a previous history of traumatic amputation of his left arm and 2 months prior to admission he was diagnosed as having a superficial grade I carcinoma of the bladder. Treatment for his bladder cancer was started with endoscopic resection followed by weekly intravesical BCG immunotherapy for 6 weeks (Immucyst BCG; Inibsa, Barcelona, Spain). One week after the last instillation, he was admitted after complaining of dysuria, malaise, pyrexia of 38.58C, pain, and swelling in his right hand, knees and right foot. At admission, physical examination revealed arthritis of the right fifth proximal interphalangeal joint, both knees, the right ankle and tarsus, swelling over the right Achilles tendon, and dactylitis in the third finger of his right foot.
Initial laboratory evaluation showed a haemoglobin concentration of 14.1 gudl, leucocytosis with left shift (11.7 3 10 9 ul white blood cells with 79.5% neutrophils), a platelet count of 278 000umm 3 , an erythrocyte sedimentation rate (ESR) of 76 mmu1st h, a C-reactive protein (CRP) concentration of 42.4 mgudl (normal range 0-0.5 mgudl) and mildly raised levels of c-glutaryl transferase (125 Uul, normal range 11-50 Uul). Two series of four blood cultures and the urine culture were sterile. Tests for rheumatoid factor and antinuclear antibodies were negative. The HLA phenotype was HLA-DRB1*08 + uDRB1*13 + and HLA-B27
The chest X-ray was normal. Examination of SF drawn from the left knee showed a turbid effusion with 64 000 cellsumm 3 with no crystals. SF was sent on two occasions for complete bacteriological analysis, including mycobacteria wZiehl-Neelsen, specific cultures and polymerase chain reaction (PCR)x, and was always sterile.
The patient was treated with indomethacin for 3 months at 150 mguday followed by 4 additional months at 100 mguday. At present, and after 19 months without therapy, the patient remains asymptomatic with no joint signs and normal CRP and ESR.
Isolation of mononuclear cells and HLA typing PBMC were purified from EDTA (ethylenediamine tetraacetic acid)-treated venous blood by Ficoll gradient centrifugation (Amersham Pharmacia Biotech, Uppsala, Sweden). DNA was extracted from PBMC with DNAzol reagent (Life Technologies, Grand Island, NY, USA) and HLA-DRB1 alleles were characterized by allele-specific PCR amplification with a Dynal All Set SSP (Dynal, Oslo, Norway). The expression of HLA-B27 was studied by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA) using a wholeblood lysis technique with commercially available monoclonal antibodies (mAb) (Becton Dickinson).
FACS analysis PB T-cell phenotype and T-cell receptor (TCR) BV variable region gene products were determined by flow cytometry using a whole-blood lysis technique. The following mAbs were used: FITC (fluorescein isothiocyanate)-conjugated mAbs against CD7, CD45RA, CD45RO, HLA-DR (Pharmingen, San Diego, CA, USA), CD25, CD28, CD57, BV2, BV3S1, BV5S1, BV5S2u5S3, BV6S7, BV8, BV13S1u13S3, BV12 and BV17 (Endogen, Woburu, MA, USA); phycoerythrin-conjugated anti-CD4 and -CD8 and FITC-conjugated anti-CD3 (Becton Dickinson). Whole-blood samples were stained within 3 h of venipuncture with two-colour direct immunofluorescence reagents, following the manufacturer's instructions. Erythrocytes were lysed using FACS 1 Lysing Solution (Becton Dickinson, San José, CA, USA). Twenty thousand cells were analysed on the day of processing, using a Becton Dickinson FACScalibur and Simulset software. The panel of mAbs against TCRBV used covered 40-60% of the T-cell repertoire, and BV-restricted expansions were defined as occurring when BV specificities were expressed at a frequency above the mean +3 S.D. of 25 young healthy donors.
T-cell proliferation assays
Short-term TCL were established from PBMC by incubating 1 3 10 6 cells for 48 h with immobilized anti-CD3 (5 mguml), followed by stimulation with recombinant human interleukin 2 (IL-2) at 20 IUuml every 48 h. After 2 weeks in IL-2-dependent culture, T cells were harvested, washed in IL-2-free medium to deplete exogenous IL-2, and stimulated in 24-well flat-bottomed culture plates at a concentration of 1 3 10 6 cellsuwell with the following antigens: BCG, tuberculin (PPD; Evans Medical, Madrid, Spain) and human hsp-60 (Sigma-Aldrich, St Louis, MO, USA). Tetanus toxoid (TT; Evans Medical) was employed as a control for T-dependent antigen stimulation. The proliferative responses were assessed by measuring bromodeoxyuridine (BrdU) incorporation after 7 days of culture, as described elsewhere w6x. After incubation, cells were collected and stained with an anti-BrdU mAb conjugated to FITC together with a PE-coupled anti-CD4 or -CD8 mAb in the presence of DNase. Thereafter, at least 20 000 cells were analysed by flow cytometry. Results were calculated as signal-to-noise (SuN) ratio using the following formula: % BrdU + cells after stimulationu % BrdU + cells without stimulation. We also kept the stimulated TCL for an additional week in IL-2-dependent culture to analyse possible changes in the TCRBV repertoire with respect to that of basal TCL before stimulation.
Results

Distribution and phenotype of SF and PB cells
In the SF, a marked increase in lymphocytes was detected, mostly due to the CD4 + T cells, with a CD4uCD8 ratio of 2.95. In contrast, there was lymphopenia in the PB of both CD4
+ and CD8 + T cell subsets at the onset of active arthritis, and the lymphopenia recovered after clinical remission (Table 1) . Flow cytometry analysis also revealed an increase in blood cytolytic T cells (CD3 + uCD16 + uCD56 + ) at the time of the arthritis episode, and this had decreased by about 30% when symptoms had disappeared ( + T cells did not show any significant deviation when compared with aged-paired control subjects. Besides, the frequencies of the different subsets of PB T cells remained unchanged after clinical recovery (data not shown).
In contrast to the PB cells, the SF cells showed an activated memory phenotype in both CD4
+ and CD8 + T-cell subsets. As shown in Fig. 1 , within the SF + T cells with a cytolytic phenotype (CD57 + ) was decreased with respect to PB.
TCR expression in PB and SF cells
The initial analysis of TCRBV expression in CD4 + T cells did not show important differences between PB and SF (Fig. 1) . However, the frequencies of BV3, BV5S1, BV5S2u5S3, BV8 and BV13.1 were higher in SF CD8
+ T cells than in PB cells. In contrast, BV17 was more frequently expressed in PB than in SF. Furthermore, we were able to detect expansions of CD8 + T cells in PB (BV17) and in SF (BV5S1 and BV12). Strikingly, the percentage of PB CD8 + T cells with TCRBV17 diminished (from 11.7 to 5.6%) when the symptoms remitted after 4 months of therapy. It was noticeable that, of the five TCRBV families that expressed higher frequencies in SF CD8 + T cells, three (BV3, BV5S1 and BV5S2u5S3) also decreased in PB CD8 + T cells during the follow-up (BV3, 2.1 to 1.7%; BV5S1, 3.1 to 2.05%; BV5S2u5S3, 4.1 to 2.3%).
Proliferative response of TCL to various mycobacteria-derived antigens Short-term TCL from the patient and a sex-and agematched control subject were tested in parallel and in duplicate for their proliferative response to BCG, PPD, human hsp-60 and TT (Fig. 2) . CD4 + TCL from both the patient and the control subject responded to BCG in a dose-dependent manner, although the response was stronger in the healthy control. The response of CD4 + TCL to PPD in both cases was to the lowest of the stimuli used and, as for BCG, was more intense in the control CD4 + TCL. Interestingly, the most important response of CD4 + TCL from the patient was against human hsp-60 and was inversely dose-dependent.
Very important was the finding that CD8 + TCL from the patient demonstrated no proliferative response to any mycobacteria or to hsp antigenic challenge. Furthermore, these cells did not respond to the TT used as control. However, CD8
+ TCL from the control subject responded efficiently to every antigen tested (Fig. 2) .
TCRBV expression after in vitro stimulation with mycobacteria-derived antigens
We further analysed whether the TCR distribution observed in the PB cells remained in the established TCL in response to BCG, PPD, human hsp-60 and TT. To this end, after antigenic challenge of TCL for 1 week, these cells were kept in culture with IL-2 for 7 additional days. There were no important differences between the patient and the control subject in the TCRBV distribution in CD4
+ TCL 14 days after the antigenic challenge in vitro (data not shown).
However, significant differences were detected in the CD8 + TCL. Two of the TCRBV families that had a higher frequency among the SF CD8
+ T cells at the onset of arthritis (TCRBV5S1 and TCRBV13) proliferated 14 days after stimulation with mycobacterial antigens and exogenous IL-2 (Fig. 3) . On the other hand, and despite the low frequency of TCRBV6.7 and TCRBV17 in SF CD8 + T cells, there was also an important proliferation of patient CD8
+ TCL expressing these TCRBV families to mycobacterial antigens. As shown in Fig. 3 , every BV family proliferated in response to one or more mycobacterial antigen, but all of them had in common a constant and clear response to human hsp-60. In the remaining BV families analysed we did not find significant differences in the proliferative response compared with the control (data not shown).
Discussion
To the best of our knowledge, this is the first report that shows CD8
+ T-cell expansions in both PB and SF of a patient with active reactive arthritis (ReA) after BCG immunotherapy for bladder cancer. Furthermore, the response of patient's T cells to several mycobacteriaderived antigens in vitro reveals the potential role of both CD4
+ and CD8 + T-cell subsets in the development of this ReA.
Although CD4 + T lymphocytes were augmented in the SF of the patient, they did not show any significant expansion. However, the CD8 + subset displayed several expansions in both the PB and SF at onset of arthritis that decreased after remission, suggesting a possible role of these lymphocytes in the development of ReA after BCG instillation, as described for other ReA w7, 8x. However, it is well known that expansions in CD8 + T cells are more common than in CD4 + T cells in both diseased and healthy aged subjects w9-12x. The phenomenon of T-cell expansion may reflect the proliferation of antigen-specific T cells, a non-specific expansion of memory T cells in response to the production of inflammatory cytokines, or a defect in T-cell homeostasis that may predispose to the disease. We consider that our results support the first hypothesis for several reasons. First, the SF CD8 + T cells showed a phenotype of activated and memory cells, as described in ReA caused by other infectious agents w7, 13x. Secondly, the BV-restricted expansions, together with the recent activation phenotype, indicate a specific stimulation of CD8 + T cells by the BCG w14x. Thirdly, in vitro stimulation with mycobacteria-derived antigens induced a higher expression of some BV families expanded in PB and SF CD8+ T cells. Although we cannot exclude non-specific T-cell proliferation in response to proinflammatory cytokines, it is also important to remark that the major TCRBV expansions observed decreased after remission of the symptoms, making the third hypothesis less probable. This can be explained by the acute and limited course of the disease, in contrast to the persistence of TCRBV expansions described in other chronic forms of ReA w15x.
On the other hand, the strong in vitro response of CD4 + TCL from the patient to mycobacterial antigens indicates their antigen-specificity and reactivity. A possible explanation is that these lymphocytes would have a helper effect by secreting cytokines that stimulate the antigen-specific CD8 + T-cell response w16x. In contrast, the in vitro stimulation of CD8 + TCL showed a state of unresponsiveness to every antigen tested. This lack of responsiveness, which was reversed after the addition of exogenous IL-2, is compatible with the state of anergy. Some authors suggest that such anergy may be the result of presentation of self-antigens by non-professional antigen-presenting cells or the influence of locally produced cytokines w17x. Indeed, some reports have shown an ineffective Th1 response, which would contribute to bacterial persistence w18x. At present, it is argued that IL-10-secreting T-cell clones act as regulator T cells that could down-regulate T CD8
+ activity w19x. Mycobacteria are intracellular pathogens that are eliminated by the cytolytic response of CD8 + cells. In this response, the antigen must be presented by HLA-I molecules w20x. In the case of mycobacteria-associated ReA after intravesical therapy, there is a clear association
FIG. 2. Proliferation of CD4
+ (left) and CD8 + (right) TCL obtained from peripheral blood of the patient with ReA (grey bars) and one aged-matched control subject (white bars). As described in Materials and methods, TCL were stimulated for 72 days with BCG, PPD and hsp-60 at 5, 2.5 and 1 mguml. TT was employed as control for stimulation. Proliferating cells were detected by staining with an anti-BrdU mAb after incorporation of BrdU. Results are expressed as signal-to-noise (SuN) ratio, calculated as the percentage of BrdU + cells after stimulation divided by the percentage of BrdU + cells without stimulation.
with HLA-B27 w21x. Our patient carried the HLA-B27 antigen, which could increase the sensitivity of lymphocytes to certain bacterial antigens w22x. Experimental work has shown cross-reactivity between mycobacterial antigens and cartilage proteins. Furthermore, hsp are major antigenic determinants and mycobacterial hsp have sequence homology with human hsp w23x. All these data together suggest the existence of a cytotoxic response triggered by BCG instillation that could be specific for HLA-B27 molecules carrying endogenous peptides, such as human hsp-60, by a molecular mimicry mechanism w15x. In fact, Zugel et al. w24x considered cross-reactivity between hsp-60 from Mycobacterium tuberculosis and human hsp-60 to be necessary in order to induce autoimmune disease. In our patient, an immune response initiated by BCG instillation may have been enhanced by cross-reactivity with the patient's self-hsp, which was presented by the HLA-B27 molecule. In summary, BCG instillation might be responsible for the activation of both CD4 + and CD8 + T cells. Thereafter, these T cells could cross-react with selfantigens, such as hsp-60. However, the present data do not clarify the nature of the antigen responsible for the activation and BV-restricted expansions described.
FIG. 3. CD8
+ TCL expressing particular TCRBV after in vitro challenge with BCG, PPD, hsp-60 and TT. Fourteen days after stimulation and culture in medium with IL-2, cells were collected and stained with specific mAbs for TCRBV families and analysed by flow cytometry. The grey bars represent the patient CD8 + TCL and the white bars represent CD8 + TCL from the control subject. Results are expressed as signal-to-noise (SuN) ratio calculated as the percentage of CD8 + TCL expressing a particular TCRBV after stimulation divided by the percentage of CD8 + TCL with the same TCRBV without stimulation.
